Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 14, 2016 8:05 AM ESTInitiated Phase 2 Trial for SY-1425 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Highlighted Research on First Selective CDK12 and CDK13 Inhibitor as Novel Approach to Treat Range of Cancers
Closed Initial Public Offering for $57.5 Million in Gross Proceeds
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) today reported financial results for the quarter ended September 30, 2016 and provided an update on recent accomplishments and upcoming events.
With the dosing... More
